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Summary
Hyperleukocytosis is a complication of various leukemias 
and can result in life-threatening leukostasis. Critical white 
blood cell (WBC) counts are conventionally defined as 
higher than 100 × 109/l in acute myeloid leukemia and 
> 300 × 109/l in acute lymphatic leukemia and other leuke-
mic disorders (e. g. chronic myeloid leukemia). Leukocyta-
pheresis is a therapeutic tool to reduce leukocyte counts in 
patients with symptomatic or threatening leukostasis until 
induction chemotherapy works. In patients with tempo-
rary contraindications against cytotoxic drugs, e.g. during 
pregnancy, leukocytapheresis can be used as a bridging 
therapy until conventional chemotherapy can be started. 
Therapeutic leukocytapheresis should be performed in 
specialized centers by experienced, well-trained staff. 
Thorough monitoring of the patients is extremely relevant. 
During a single procedure, WBC count can be reduced by 
10–70%. Treatment should be repeated daily and can be 
discontinued when the symptoms of leukostasis have 
been resolved and/or leukocyte counts have fallen below 
the critical thresholds. There are no prospective studies 
evaluating the clinical efficacy of therapeutic leukocyt-
apheresis in patients with hyperleukocytosis. It can be con-
cluded from retrospective studies that leukocytapheresis 
might have some beneficial effect in early morbidity and 
mortality of patients with newly diagnosed AML but has 
no influence on overall long-term survival. Induction 
chemotherapy is the most important treatment in these 
patients and must never be postponed. 
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Zusammenfassung
Leukozytose ist eine Komplikation verschiedener Leukä-
mien und kann zur lebensbedrohlichen Leukostase führen. 
Als kritische Leukozytenzahlen gelten im Allgemeinen 
Werte über 100 × 109/l bei akuten myeloischen Leukämien 
und über 300 × 109/l bei akuter lymphatischer Leukämie 
und anderen Leukämieformen (z. B. chronisch-myeloische 
Leukämie). Mittels therapeutischer Leuko zytapherese kön-
nen pathologisch erhöhte Leukozytenwerte bei Patienten 
mit symptomatischer oder drohender Leukostase reduziert 
werden, bis die Wirkung der Induktions-Chemotherapie 
einsetzt. Bei Patienten mit vorübergehenden Kontraindika-
tionen gegen Zytostatika, wie z.B. in der Schwangerschaft, 
dient die Leukozytapherese zur Überbrückung des Zeit-
raums, bis die konventionelle Chemotherapie begonnen 
werden kann. Leukozytapheresen sollten nur in speziali-
sierten Zentren von erfahrenem, geschultem Personal 
durchgeführt werden. Eine sorgfältige Überwachung der 
Patienten ist von besonderer Bedeutung. Während einer 
Behandlung kann die Leukozytenzahl um 10–70% reduziert 
werden. Die Behandlung sollte täglich wiederholt werden, 
bis die Leukostasesymptomatik abgeklungen bzw. die Leu-
kozytenzahl unter die kritische Interventionsschwelle abge-
fallen ist. Es mangelt an prospektiven, randomisierten, 
kontrollierten Studien, die den klinischen Effekt der thera-
peutischen Leukozytapherese bei Patienten mit Leukostase 
evaluieren. Retrospektive Studien lassen auf eine thera-
peutische Wirksamkeit der Leukozytapherese hinsichtlich 
Frühmorbidität und –mortalität bei Patienten mit neu diag-
nostizierter AML schließen. Ein Einfluss dieser Therapie 
auf das Gesamtüberleben von AML-Patienten konnte nicht 
nachgewiesen werden. Die entscheidende Therapie für 
diese Patienten ist die Induktions-Chemotherapie, die des-
halb auch keinesfalls verzögert werden sollte. 
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leukostasis. Up to now, this grading system has not yet been 
clinically validated but it might be an interesting tool for 
 future studies 
The critical WBC count, giving rise for therapeutic inter-
vention, is not clearly defined. The incidence and severity of 
leukostatic symptoms seem to be essentially dependent on the 
type of leukemia. The risks seem to be particularly high in 
acute myeloid leukemia (AML), where WBC counts between 
50 and 100 × 109/l are regarded dangerous and an indication 
for leukocytapheresis. Leukocyte counts >300 × 109/l in AML 
patients resemble an absolute indication for leukocytapher-
esis. In chronic-myeloid leukemia and lymphatic leukemias, a 
substantial risk of leukostasis seems to arise only with WBC 
counts remarkable higher than 300 × 109/l. Because of the low 
number of studies published the level of evidence of leuko-
cyte depletion by leukocytapheresis is mostly low (IIc, see 
[6]). Prospective randomized trials have not yet been re-
ported. The indications for therapeutic leukapheresis are 
summarized in table 2. 
Leukocytapheresis is contraindicated in AML FAB M3 
(APL) because of the accompanying disseminated intravascu-
lar coagulation which is characteristic for this subtype of 
AML [7]. There are no other absolute contraindications. Rel-
ative contraindications such as anemia, thrombocytopenia, 
systemic infections, and respiratory or circulatory insuffi-
ciency can be negotiated provided that adequate supportive 
treatment is done.  
Basic Principles
Leukocytapheresis, according to the ASFA guidelines, means 
a procedure in which blood of the patient or the donor is 
passed through a medical device, which separates out WBCs 
(e.g. leukemic blasts or granulocytes), collects the selected 
cells, and returns the remainder of the patient’s or the do-
nor’s blood with or without addition of replacement fluid 
such as colloid, human albumin, and/or crystalloid solution 
[6]. In modern apheresis devices (blood cell separators) 
WBCs and their precursors are separated from patient’s 
blood by centrifugation. Therapeutic leukocytaphereses 
should only be performed in centers with a certain degree of 
experience in this method of blood cell separation. Apheresis 
units routinely collecting peripheral blood stem cells or 
 granulocyte concentrates normally have the skills necessary 
to perform the procedure. Physicians and nurses trained in 
Introduction 
Therapeutic leukocytapheresis is a symptomatical treatment 
of hyperleukocytosis in acute and chronic leukemias. The ob-
jective of this procedure is to reduce highly elevated WBC 
counts in order to prevent or to treat leukostatic syndrome. 
Leukostasis is regarded as a major prognostic factor for early 
mortality in acute leukemias [1]. Leukocytes and especially 
leukemic blasts are less deformable than red cells. A massive 
elevation of this cell population is associated with an increase 
of blood viscosity [2]. This can give rise to occlusion of blood 
vessels with ischemia, hypoxia, and endothelial damage. An-
other aspect of the pathogenesis may be the activation of en-
dothelial cells by blast secreted cytokines (TNF-_ and IL-1`) 
and interactions between leukemic and endothelial cells by 
adhesion molecules (e.g. selectins and VCAM-1). Both mech-
anisms might as well act synergistically to promote the leuko-
static syndrome [3].
Tissue hemorrhage and loss of organ functions are second-
ary consequences of these pathologic events. Furthermore, 
there is an increasing risk of leukemic infiltration in the or-
gans involved. 
Typical organ manifestations of leukostasis are the lung 
vasculature and the central nervous system (CNS). The clini-
cal symptoms of leukostasis are specified in table 1.
Embolism of periphery arteries with ischemic lesion of cor-
responding extremities is reported in some clinical cases [4]. 
Priapism in male patients due to leukostasis represents a spe-
cial emergency situation. Novotny et al. [5] proposed a risk 
score for the probability of leukostasis in patients with leuke-
mia and hyperleukocytosis. They divided their patients into 
four groups – none, possible, probable, and highly probable 
Table 1. Symptoms of leukostasis 
Organ Symptoms
Lung dyspnea, hypoxemia, diffuse alveolar  
hemorrhage, respiratory failure
Central nervous system confusion, somnolence, dizziness, headache, 
delirium, coma, focal neurological deficits
Eye impaired vision, retinal hemorrhage 
Ear tinnitus
Heart myocardial ischemia/infarction
Vascular system limb ischemia, renal vein thrombosis,  
priapism
Indication Recommendation Category
AML, WBC >100 × 109/l grade IB I (leukostasis)
ALL, WBC > 400 × 109/l grade IIC III (prophylaxis)
Other leukemias, WBC > 400 × 109/l with leukostasis grade IC not categorized by ASFA
Other leukemias, WBC > 400 × 109/l without leukostasis grade IIC not categorized by ASFA
Table 2. Indications 
for therapeutic leuko-
cytapheresis (according 
to the Guidelines of 
the American Society 
for Apheresis (ASFA) 
[6], with addition)
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if the separation of red cells, WBCs and plasma cannot be 
observed correctly or if the color of the apheresis product is 
dark-red, indicating a high hematocrit. The use of sediment-
ing agents like hydroxyethyl starch (HES) is not required and 
disregarded by ASFA [6]. According to other apheresis treat-
ments, patients should be asked for paresthesia due to hypo-
calcemia and receive calcium supplementation if necessary. 
In patients with poor general condition and in children, cal-
cium and potassium levels should be monitored hourly and 
corrected by intravenous infusion. Furthermore, continuous 
measurement of oxygen saturation by pulse oximetry and 
noninvasive monitoring of arterial blood pressure and heart 
rate are recommended in these patients. General aspects of 
therapeutic aphereses in pediatric patients have been re-
ported elsewhere [8, 9].    
The volume of the leukocytapheresis product ranges from 
200 to 1,000 ml, depending on the type of blood cell separator 
used and the patient’s blood volume processed. If more than 
20% of the patient’s blood volume are collected, fluid re-
placement with colloids or human albumin is recommended. 
Red cell transfusion should be performed only at the end of 
the leucocytapheresis procedure, whenever possible, to avoid 
further increase of blood viscosity [10]. Complete blood 
count, electrolytes, and coagulation parameters should be 
 determined at the beginning and the end of the procedure; 
pathological findings should be shared with the attending 
physicians. Therapeutical leukocytaphereses can be repeated 
daily until symptoms of leukostasis have disappeared or the 
WBC target count (in AML usually below 100 × 109/l, in 
other leukemias below 200 × 109/l) is reached. There is no 
clinical rationale to perform more than one treatment per 
day. In pregnant women and other patients with temporary 
contraindications to cytotoxic drugs, leukocytapheresis can 
be repeated for longer periods until chemotherapy can be 
started.
intensive care medicine are needed if the patients are in bad 
clinical condition, what might often be the case. In these pa-
tients, monitoring of blood pressure, heart rate, ECG, and O2 
saturation as well as oxygen supply are strongly recom-
mended. Immediate transfer of the patient to an intensive 
care unit, if necessary, must be possible. Sometimes it can be 
necessary to move the apheresis equipment to an intensive 
care unit and perform the treatment at bedside. On the scale 
of things, close cooperation between Transfusion Medicine, 
Hematology, Pediatrics and Anesthesiology/Intensive Care 
Medicine is essential.
Performance
Informed consent of the patient or legal guardian has to be 
obtained before initiation of the treatment. If the patient is 
not able to agree and it is a life-threatening emergency situa-
tion, this has to be documented too. Peripheral venous access 
should be used for the leucocytapheresis procedure when-
ever possible in order to avoid delay and bleeding complica-
tions in these often thrombocytopenic patients. Impairment 
of cellular and plasmatic coagulation has to be considered 
during anticoagulation. Normally, citrate is the anticoagulant 
of choice, and the citrate/blood ratio should be kept as high 
as possible (i.e. 1:16 to 1:20). Heparin should not be applied 
because of its long-lasting systemic inhibitory effects on co-
agulation. The leukocytapheresis procedure has to be ad-
justed to the type of leukemia and other characteristics of the 
patient such as hematocrit, platelet count, and blood volume. 
The blood volume to process should be between 2 and 4 
times the patient’s blood volume. Under optimal conditions, 
the hematocrit of the apheresis product ranges from 3 to 5%. 
In some forms of leukemia, it can be reasonable to increase 
the speed of rotation of the centrifuge to improve sedimenta-
tion of the leukemic blasts. This should always be considered, 
Table 3. Published reports on the efficacy of leucocytapheresis in patients with hyperleukocytosis 
Reference Number of patients Clinical results
Bug et al., 2007 [12] 53, AML, 25 treated with leukocytapheresis leukocytapheresis significantly reduced 3 week mortality;  
overall survival after a follow-up of 24 months did not  
differ significantly
Kuo et al., 2006 [13] 89, AML, 42 treated with leukocytapheresis,  
47 received hydroxyurea
identical survival rates at day 8 (p = 1.00) and day 28  
(p = 0.4784)
Giles et al., 2001 [14] 146, AML/ 71 treated with leukocytapheresis 2 week mortality was reduced (p = 0.006), trend to a higher  
rate of CR (p = 0.06); no impact on overall survival
Porcu et al., 1997 [15] 48 patients (AML or CML blast crisis) treated  
with leukocytapheresis, no control group
early mortality 27%, according to the literature,  
no correlation of cytoreduction and survival rate
Cuttner et. al., 1983[16] 22 patients (AML) >30% reduction of WBC count correlated well with the  
attainment of remission
Thibaut et al., 2000 [17] 53 patients, no control group early mortality 3.7%, lower than in the literature 
Lowe et al., 2005 [18] 178 pediatric patients (ALL), 94 treated with  
leukocytapheresis
effective reduction of leukocyte count, but delayed initiation  
of chemotherapy
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Discussion and Conclusions
Although leukocytapheresis has been established about 50 
years ago, its place in the therapeutical algorithm of leuke-
mias is still uncertain. The technical aspects of the procedure 
are difficult to standardize because of the heterogeneity of 
leukemic cell populations. The infrequence of patients with 
hyperleukocytosis limits the possibility to acquire routine 
even in large centers. On the other hand, the efficacy of leu-
kocyte reduction correlates not only with the amount of cells 
removed but also with growth pattern and distribution kinet-
ics of the leukemic blasts. Both the technical aspects and the 
pathophysiology explain the large variation of leukocyte re-
duction that can be achieved in individual patients during a 
single treatment.
The body of evidence from the literature does not reveal a 
clear proof of an advantage of therapeutic leucocytapheresis 
compared with conventional cytoreductive treatment regard-
ing long-term survival in any form of leukemia. These data 
indicate that hyperleukocytosis correlates with other poor 
prognostic factors, especially in AML and ALL, that cannot 
be modified by cytoreductive treatment [19].
On the contrary, there are patients who unequivocally ben-
efit from the immediate leukocyte depletion, e.g. patients with 
priapism or coma due to leukostasis. The question which pa-
tients with asymptomatic hyperleukocytosis are at risk to de-
velop life-threatening complications of leukostasis and would 
profit from leukocytapheresis remains intricate. A grading 
system like that proposed by Novotny et al. [5] might support 
therapeutic decisions in the future. 
According to current knowledge, the following recommen-
dations can be made:
– Hyperleukocytosis in acute leukemia represents an emer-
gent situation requiring appropriate therapy without any 
delay.
– Early initiation of chemotherapy, hydroxyurea and sup-
portive care are the therapeutical fundament and must be 
guaranteed.
– Patients with clear symptoms of leukostasis should undergo 
leukocytapheresis in a timely manner. The treatment has 
to be performed in a center with experience in leukocyt-
apheresis and emergency equipment. Leukocytapheresis 
procedures should be repeated daily until leukostatic 
symptoms have disappeared and WBC count has reached 
safe values. 
– In asymptomatic patients with hyperleukocytosis the deci-
sion for treatment remains at the discretion of the attend-
ing physician [11].
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Clinical Results
In patients with leukostasis a single treatment frequently 
causes remarkable improvement. During a single leukapher-
esis, the WBC count can be reduced by 10–70%. The thera-
peutical benefit of leukocytapheresis has been investigated 
particularly in patients with AML and in pediatric patients 
with acute lymphatic leukemia (ALL) (table 3). Unfortu-
nately there have been no prospective studies published to 
date. In 2 retrospective studies with a control group (Giles et 
al. [12], Bug et al. [14]), a beneficial effect of leukocytapher-
esis on early morbidity and mortality of patients with newly 
diagnosed AML could be detected, but the authors did not 
observe any influence on long-term survival. Another retro-
spective study comparing the management of 89 AML pa-
tients with leukocytapheresis versus hydroxyurea demon-
strated equivalent survival on days 8 and 28 [13]. The study of 
Porcu et al. [15] did not reveal any difference in early mortal-
ity in patients treated with leukocytaperesis compared with 
the literature. Altogether there is very little evidence that 
therapeutic leukocytapheresis has a substantial impact on the 
outcome of adult AML patients with leukostasis. In the pedi-
atric population, ALL often presents with hyperleukocytosis 
at time of diagnosis. Lowe et al. [18] retrospectively analyzed 
178 children with ALL and hyperleukocytosis; 94 had been 
treated with therapeutical leukocytapheresis. The authors re-
ported that leukocytapheresis decreased the leukocyte count 
but also delayed the initiation of chemotherapy (p =  0,013). 
In our own center, between 5 and 10 patients per year are 
treated with therapeutic leukapheresis. According to other re-
ports, about 90% suffer from AML. Symptoms of leukostasis 
were detected in about 30% of the patients. In most cases, 
only one leukocytapheresis was performed. The reduction of 
leukocyte count ranged from 23 to 70% and did not correlate 
to the volume of the apheresis product. The treatment itself 
was well tolerated by all patients. Due to the lack of a control 
group, no long-term advantage of leukocyte depletion could 
be shown. In a group of 15 patients treated between 1997 and 
2006, early mortality was 27%, corresponding with the 
literature.  
Risks and Side Effects
All in all, besides the often critical overall condition of the pa-
tients with leukostasis, there have been no severe adverse 
events of leukocytapheresis published yet. Thrombocytopenia 
and coagulation disorders due to the underlying disease may 
be triggered by the cell separation procedure and the antico-
agulation and should be treated adequately. Properly con-
ducted, the treatment is well tolerated without major side 
effects. 
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